Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by IndexIQ Advisors LLC

IndexIQ Advisors LLC raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 5.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,945 shares of the company’s stock after buying an additional 330 shares during the period. IndexIQ Advisors LLC’s holdings in Moderna were worth $2,288,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MRNA. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of Moderna by 29.3% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 58,660 shares of the company’s stock valued at $13,784,000 after purchasing an additional 13,292 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in Moderna by 73.6% during the second quarter. O Shaughnessy Asset Management LLC now owns 1,759 shares of the company’s stock valued at $413,000 after acquiring an additional 746 shares in the last quarter. Toronto Dominion Bank raised its position in shares of Moderna by 13.9% in the second quarter. Toronto Dominion Bank now owns 43,798 shares of the company’s stock valued at $10,292,000 after purchasing an additional 5,335 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Moderna by 23.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 6,540 shares of the company’s stock worth $1,537,000 after acquiring an additional 1,257 shares during the last quarter. Finally, Marcum Wealth LLC acquired a new stake in shares of Moderna in the second quarter worth $235,000. Institutional investors own 59.11% of the company’s stock.

In related news, CEO Stephane Bancel sold 9,000 shares of the stock in a transaction dated Wednesday, October 20th. The stock was sold at an average price of $333.90, for a total transaction of $3,005,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Stephen Hoge sold 20,000 shares of the stock in a transaction that occurred on Monday, October 25th. The stock was sold at an average price of $331.80, for a total value of $6,636,000.00. The disclosure for this sale can be found here. Insiders sold a total of 419,000 shares of company stock valued at $118,092,130 over the last quarter. Company insiders own 19.40% of the company’s stock.

MRNA has been the topic of several recent analyst reports. TheStreet upgraded shares of Moderna from a “c+” rating to a “b-” rating in a research note on Monday, November 1st. Piper Sandler decreased their price objective on Moderna to $348.00 and set an “overweight” rating for the company in a research report on Friday, November 5th. Deutsche Bank Aktiengesellschaft started coverage on Moderna in a research report on Friday, October 22nd. They set a “sell” rating and a $250.00 price target for the company. Argus dropped their price objective on Moderna from $420.00 to $350.00 in a research note on Thursday, January 6th. Finally, Morgan Stanley dropped their price target on Moderna from $337.00 to $313.00 and set an “equal weight” rating on the stock in a research note on Friday, November 5th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $251.81.

Shares of MRNA opened at $204.73 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.35 and a quick ratio of 1.25. Moderna, Inc. has a 1 year low of $117.34 and a 1 year high of $497.49. The firm has a market cap of $83.01 billion, a PE ratio of 12.55, a PEG ratio of 0.28 and a beta of 1.22. The stock’s fifty day moving average price is $259.66 and its two-hundred day moving average price is $320.60.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 4th. The company reported $7.70 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.49 by ($1.79). The company had revenue of $4.97 billion for the quarter, compared to the consensus estimate of $6.29 billion. Moderna had a net margin of 59.69% and a return on equity of 121.61%. The business’s revenue for the quarter was up 3065.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.59) earnings per share. Sell-side analysts anticipate that Moderna, Inc. will post 26.32 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: Shanghai Stock Exchange Composite Index

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.